APO Research
Talk to an analyst

APO RESEARCH · REPORT

Osteoarthritis Autologous Chondrocyte Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Osteoarthritis Autologous Chondrocyte Therapy Market Analysis and Forecast 2026-2032

26 December 2025199 pages

Choose your research edition.

Industry ResearchOsteoarthritis Autologous Chondrocyte Therapy Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Osteoarthritis Autologous Chondrocyte Therapy Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal Osteoarthritis Autologous Chondrocyte Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Osteoarthritis Autologous Chondrocyte Therapy Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Osteoarthritis Autologous Chondrocyte Therapy Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Osteoarthritis Autologous Chondrocyte Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Osteoarthritis Autologous Chondrocyte Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Osteoarthritis Autologous Chondrocyte Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Osteoarthritis Autologous Chondrocyte Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Osteoarthritis Autologous Chondrocyte Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Osteoarthritis Autologous Chondrocyte Therapy include CO.DON GmbH, Japan Tissue Engineering, Orthocell and Vericel, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Osteoarthritis Autologous Chondrocyte Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Osteoarthritis Autologous Chondrocyte Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Osteoarthritis Autologous Chondrocyte Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Osteoarthritis Autologous Chondrocyte Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Osteoarthritis Autologous Chondrocyte Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Osteoarthritis Autologous Chondrocyte Therapy revenue, projected growth trends, production technology, application and end-user industry.

Osteoarthritis Autologous Chondrocyte Therapy Segment by Company

CO.DON GmbH

Japan Tissue Engineering

Orthocell

Vericel

Osteoarthritis Autologous Chondrocyte Therapy Segment by Type

2nd Gen C-ACI

3rd Gen M-ACI

Osteoarthritis Autologous Chondrocyte Therapy Segment by Application

Primary Osteoarthritis

Secondary Osteoarthritis

Osteoarthritis Autologous Chondrocyte Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osteoarthritis Autologous Chondrocyte Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Osteoarthritis Autologous Chondrocyte Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osteoarthritis Autologous Chondrocyte Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Osteoarthritis Autologous Chondrocyte Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Osteoarthritis Autologous Chondrocyte Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Osteoarthritis Autologous Chondrocyte Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Osteoarthritis Autologous Chondrocyte Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 2nd Gen C-ACI Major Player Table 3. 3rd Gen M-ACI Major Player Table 4. Global Osteoarthritis Autologous Chondrocyte Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Primary Osteoarthritis Major Player Table 6. Secondary Osteoarthritis Major Player Table 7. Osteoarthritis Autologous Chondrocyte Therapy Industry Trends Table 8. Osteoarthritis Autologous Chondrocyte Therapy Industry Drivers Table 9. Osteoarthritis Autologous Chondrocyte Therapy Industry Opportunities and Challenges Table 10. Osteoarthritis Autologous Chondrocyte Therapy Industry Restraints Table 11. Global Osteoarthritis Autologous Chondrocyte Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Osteoarthritis Autologous Chondrocyte Therapy Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Osteoarthritis Autologous Chondrocyte Therapy Market Share by Region (2021-2026) Table 14. Global Osteoarthritis Autologous Chondrocyte Therapy Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Osteoarthritis Autologous Chondrocyte Therapy Market Share by Region (2027-2032) Table 16. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue Market Share by Players (2021-2026) Table 18. Global Osteoarthritis Autologous Chondrocyte Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Osteoarthritis Autologous Chondrocyte Therapy Key Players Headquarters & Area Served Table 20. Global Osteoarthritis Autologous Chondrocyte Therapy Players, Product Type & Application Table 21. Global Osteoarthritis Autologous Chondrocyte Therapy Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Osteoarthritis Autologous Chondrocyte Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue Market Share by Type (2021-2026) Table 28. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue Market Share by Type (2027-2032) Table 29. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue Market Share by Application (2021-2026) Table 33. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue Market Share by Application (2027-2032) Table 34. CO.DON GmbH Company Information Table 35. CO.DON GmbH Business Overview Table 36. CO.DON GmbH Osteoarthritis Autologous Chondrocyte Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. CO.DON GmbH Osteoarthritis Autologous Chondrocyte Therapy Product Portfolio Table 38. CO.DON GmbH Recent Development Table 39. Japan Tissue Engineering Company Information Table 40. Japan Tissue Engineering Business Overview Table 41. Japan Tissue Engineering Osteoarthritis Autologous Chondrocyte Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Japan Tissue Engineering Osteoarthritis Autologous Chondrocyte Therapy Product Portfolio Table 43. Japan Tissue Engineering Recent Development Table 44. Orthocell Company Information Table 45. Orthocell Business Overview Table 46. Orthocell Osteoarthritis Autologous Chondrocyte Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Orthocell Osteoarthritis Autologous Chondrocyte Therapy Product Portfolio Table 48. Orthocell Recent Development Table 49. Vericel Company Information Table 50. Vericel Business Overview Table 51. Vericel Osteoarthritis Autologous Chondrocyte Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Vericel Osteoarthritis Autologous Chondrocyte Therapy Product Portfolio Table 53. Vericel Recent Development Table 54. North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2026) & (US$ Million) Table 55. North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2027-2032) & (US$ Million) Table 56. North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2026) & (US$ Million) Table 57. North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2027-2032) & (US$ Million) Table 58. North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 59. North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021-2026) & (US$ Million) Table 60. North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (US$ Million) & (2027-2032) Table 61. Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2026) & (US$ Million) Table 62. Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2027-2032) & (US$ Million) Table 63. Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2026) & (US$ Million) Table 64. Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2027-2032) & (US$ Million) Table 65. Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 66. Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021-2026) & (US$ Million) Table 67. Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (US$ Million) & (2027-2032) Table 68. China Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2026) & (US$ Million) Table 69. China Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2027-2032) & (US$ Million) Table 70. China Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2026) & (US$ Million) Table 71. China Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2027-2032) & (US$ Million) Table 72. Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2026) & (US$ Million) Table 73. Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2027-2032) & (US$ Million) Table 74. Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2026) & (US$ Million) Table 75. Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2027-2032) & (US$ Million) Table 76. Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 77. Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Region (US$ Million) & (2021-2026) Table 78. Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Region (US$ Million) & (2027-2032) Table 79. SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2026) & (US$ Million) Table 80. SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2027-2032) & (US$ Million) Table 81. SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2026) & (US$ Million) Table 82. SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2027-2032) & (US$ Million) Table 83. SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 84. SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021-2026) & (US$ Million) Table 85. SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (US$ Million) & (2027-2032) Table 86. Research Programs/Design for This Report Table 87. Authors List of This Report Table 88. Secondary Sources Table 89. Primary Sources List of Figures Figure 1. Osteoarthritis Autologous Chondrocyte Therapy Image Figure 2. Global Osteoarthritis Autologous Chondrocyte Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Osteoarthritis Autologous Chondrocyte Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. 2nd Gen C-ACI Image Figure 5. 3rd Gen M-ACI Image Figure 6. Global Osteoarthritis Autologous Chondrocyte Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Osteoarthritis Autologous Chondrocyte Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Primary Osteoarthritis Image Figure 9. Secondary Osteoarthritis Image Figure 10. Global Osteoarthritis Autologous Chondrocyte Therapy Market Size (US$ Million) & (2021-2032) Figure 11. Global Osteoarthritis Autologous Chondrocyte Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Osteoarthritis Autologous Chondrocyte Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Osteoarthritis Autologous Chondrocyte Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue Market Share by Type (2021-2032) Figure 18. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Osteoarthritis Autologous Chondrocyte Therapy Revenue Market Share by Application (2021-2032) Figure 21. North America Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Type (2021-2032) Figure 23. North America Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Application (2021-2032) Figure 24. North America Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Country (2021-2032) Figure 25. United States Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Type (2021-2032) Figure 30. Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Application (2021-2032) Figure 31. Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Country (2021-2032) Figure 32. Germany Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Type (2021-2032) Figure 42. China Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Application (2021-2032) Figure 43. Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Type (2021-2032) Figure 45. Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Application (2021-2032) Figure 46. Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Region (2021-2032) Figure 47. Japan Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Type (2021-2032) Figure 55. SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Application (2021-2032) Figure 56. SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Country (2021-2032) Figure 57. Brazil Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Osteoarthritis Autologous Chondrocyte Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • 2nd Gen C-ACI
  • 3rd Gen M-ACI
Applications
  • Primary Osteoarthritis
  • Secondary Osteoarthritis
Companies covered
  • CO.DON GmbH
  • Japan Tissue Engineering
  • Orthocell
  • Vericel

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Osteoarthritis Autologous Chondrocyte Therapy Market by Type
  3. 1.2.1 Global Osteoarthritis Autologous Chondrocyte Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 2nd Gen C-ACI
  5. 1.2.3 3rd Gen M-ACI
  6. 1.3 Osteoarthritis Autologous Chondrocyte Therapy Market by Application
  7. 1.3.1 Global Osteoarthritis Autologous Chondrocyte Therapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Primary Osteoarthritis
  9. 1.3.3 Secondary Osteoarthritis
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Osteoarthritis Autologous Chondrocyte Therapy Market Dynamics
  1. 2.1 Osteoarthritis Autologous Chondrocyte Therapy Industry Trends
  2. 2.2 Osteoarthritis Autologous Chondrocyte Therapy Industry Drivers
  3. 2.3 Osteoarthritis Autologous Chondrocyte Therapy Industry Opportunities and Challenges
  4. 2.4 Osteoarthritis Autologous Chondrocyte Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Osteoarthritis Autologous Chondrocyte Therapy Market Perspective (2021-2032)
  2. 3.2 Global Osteoarthritis Autologous Chondrocyte Therapy Growth Trends by Region
  3. 3.2.1 Global Osteoarthritis Autologous Chondrocyte Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Osteoarthritis Autologous Chondrocyte Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Osteoarthritis Autologous Chondrocyte Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Players
  2. 4.1.1 Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Osteoarthritis Autologous Chondrocyte Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Osteoarthritis Autologous Chondrocyte Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Osteoarthritis Autologous Chondrocyte Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Osteoarthritis Autologous Chondrocyte Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Osteoarthritis Autologous Chondrocyte Therapy Players, Product Type & Application
  8. 4.5 Global Osteoarthritis Autologous Chondrocyte Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Osteoarthritis Autologous Chondrocyte Therapy Market CR5 and HHI
  11. 4.6.3 2025 Osteoarthritis Autologous Chondrocyte Therapy Tier 1, Tier 2, and Tier 3
5 Osteoarthritis Autologous Chondrocyte Therapy Market Size by Type
  1. 5.1 Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Osteoarthritis Autologous Chondrocyte Therapy Revenue Market Share by Type (2021-2032)
6 Osteoarthritis Autologous Chondrocyte Therapy Market Size by Application
  1. 6.1 Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Osteoarthritis Autologous Chondrocyte Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 CO.DON GmbH
  2. 7.1.1 CO.DON GmbH Company Information
  3. 7.1.2 CO.DON GmbH Business Overview
  4. 7.1.3 CO.DON GmbH Osteoarthritis Autologous Chondrocyte Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 CO.DON GmbH Osteoarthritis Autologous Chondrocyte Therapy Product Portfolio
  6. 7.1.5 CO.DON GmbH Recent Developments
  7. 7.2 Japan Tissue Engineering
  8. 7.2.1 Japan Tissue Engineering Company Information
  9. 7.2.2 Japan Tissue Engineering Business Overview
  10. 7.2.3 Japan Tissue Engineering Osteoarthritis Autologous Chondrocyte Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Japan Tissue Engineering Osteoarthritis Autologous Chondrocyte Therapy Product Portfolio
  12. 7.2.5 Japan Tissue Engineering Recent Developments
  13. 7.3 Orthocell
  14. 7.3.1 Orthocell Company Information
  15. 7.3.2 Orthocell Business Overview
  16. 7.3.3 Orthocell Osteoarthritis Autologous Chondrocyte Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Orthocell Osteoarthritis Autologous Chondrocyte Therapy Product Portfolio
  18. 7.3.5 Orthocell Recent Developments
  19. 7.4 Vericel
  20. 7.4.1 Vericel Company Information
  21. 7.4.2 Vericel Business Overview
  22. 7.4.3 Vericel Osteoarthritis Autologous Chondrocyte Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Vericel Osteoarthritis Autologous Chondrocyte Therapy Product Portfolio
  24. 7.4.5 Vericel Recent Developments
8 North America
  1. 8.1 North America Osteoarthritis Autologous Chondrocyte Therapy Revenue (2021-2032)
  2. 8.2 North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country
  11. 8.6.1 North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue (2021-2032)
  2. 9.2 Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country
  11. 9.6.1 Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Osteoarthritis Autologous Chondrocyte Therapy Revenue (2021-2032)
  2. 10.2 China Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2027-2032)
  5. 10.3 China Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2027-2032)
  9. 10.5 China Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue (2021-2032)
  2. 11.2 Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country
  11. 11.6.1 Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country
  11. 12.6.1 SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Osteoarthritis Autologous Chondrocyte Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst